Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Triggering global regulatory submissions this year for the treatment of obesity
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Subscribe To Our Newsletter & Stay Updated
